Browsing by Author "Godfrey, Catherine"

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1

Cespedes, Michelle S. et al. | Date Issued: 2018

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

Apornpong, Tanakorn et al. | Date Issued: 2021

Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study

Scarsi, Kimberly K et al. | Date Issued: 2019

As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial

Hosseinipour, Mina C. et al. | Date Issued: 2018

Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy

Godfrey, Catherine et al. | Date Issued: 2020

Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol A5227

Vogler, Mary A. et al. | Date Issued: 2014

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings

Wallis, Carole L. et al. | Date Issued: 2020

Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy

Nyirenda, Mulinda et al. | Date Issued: 2020

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1– infected women

Kojic, Erna Milunka et al. | Date Issued: 2014

Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial

Gross, Robert et al. | Date Issued: 2015

Partner-focused adherence intervention for second-line antiretroviral therapy: a multinational randomized trial (ACTG A5234)

Gross, Robert et al. | Date Issued: 2015

Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings

Epeldegui, Marta et al. | Date Issued: 2023

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance

Salata, Robert A. et al. | Date Issued: 2023

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Grinsztejn, Beatriz et al. | Date Issued: 2019

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Avihingsanon, Anchalee et al. | Date Issued: 2022

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial

Krown, Susan E. et al. | Date Issued: 2020

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial

Gross, Robert et al. | Date Issued: 2019